Showing results (131-140 of 176) with videos related to

Sort By:
Pageof 18
Science Progress|March 19, 2025
The combination of immune checkpoint inhibitor and chemotherapy may be efficacious for advanced non-small cell lung cancer with near-loop insertions of EGFR exon 20: A retrospective analysisKe-Jun Liu, Hong-Rui Li, Quan-Quan Tan, et al.
Thoracic Cancer|July 7, 2018
Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancerJin Kang, Hua-Jun Chen, Xu-Chao Zhang, et al.
Investigational New Drugs|October 14, 2020
A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancerJin-Ji Yang, Jian Fang, Yong-Qian Shu, et al.
Ebiomedicine|April 28, 2019
Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trialYi-Chen Zhang, Zhi-Hong Chen, Xu-Chao Zhang, et al.
Cancer Cell|August 13, 2021
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 studyQing Zhou, Chong-Rui Xu, Ying Cheng, et al.
Clinical & Translational Immunology|June 5, 2024
Plasma EBV quantification is associated with the efficacy of immune checkpoint blockade and disease monitoring in patients with primary pulmonary lymphoepithelioma-like carcinomaYu-Min Zhong, Ji Chen, Jie Jiang, et al.
Thoracic Cancer|April 8, 2022
Intratumoral genetic and immune microenvironmental heterogeneity in T4N0M0 (diameter ≥ 7 cm) non-small cell lung cancersJia Tao Zhang, Song Dong, Li Yan Ji, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 20, 2019
Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLCMei-Mei Zheng, Yang-Si Li, Ben-Yuan Jiang, et al.
Thoracic Cancer|September 7, 2021
High SHP2 expression determines the efficacy of PD-1/PD-L1 inhibitors in advanced KRAS mutant non-small cell lung cancerHui-Bo Feng, Yu Chen, Zhi Xie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2019
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II StudyWen-Zhao Zhong, Ke-Neng Chen, Chun Chen, et al.
Pageof 18